Latest news

1st edition of the Days of the "antibody CLub" of the French Society of Immunology

Thu - 09, 11/08 - 09/2018 - 08:30

Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin

Read more

ElsaLys Biotech at BIO-Europe 2018

Mon - 07, 11/05 - 07/2018 - 09:00

Do not hesitate to contact us if you want to meet our team during Bio-Eu

Read more

New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases

Mon, 07/02/2018 - 17:00
  • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
  • Anti-CD160 is a potent inhibitor of ocular v
Read more

LEUKOTAC® takes next step in paediatric acute steroid-resistant GvHD

Thu, 04/05/2018 - 09:00

  • ELSALYS BIOTECH plans to submit to the European Medicines Agency before summer 2018 a Paediatric Investigation Plan (PIP) proposing to c

Read more

LEUKOTAC® at the 44th congress of the European Society for Blood and Marrow Transplantation (EBMT)

Thu, 03/15/2018 - 17:00

  • A poster summarising the safety profile results of the randomised Phase 3 testing LEUKOTAC® in patients with steroid-resistant acute gra

Read more

ELSALYS BIOTECH concludes with THEA a license option agreement on its ELB011 program in ophthalmology

Thu, 02/22/2018 - 17:00

  • ELB011, a first-in-class antibody program, demonstrates an anti-angiogenic effect on the formation of new blood vessels which cause cert

Read more

ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®, an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease

Thu, 10/12/2017 - 17:00

  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® i

Read more

ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU

Tue, 07/18/2017 - 17:00

  • With the support of the EU program Eurostar*, ELSALYS BIOTECH & DKFZ initiate the preclinical development of this next-generation im

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subcribe to our newsletter

Subscribe now

Copyright 2021 ElsaLys Biotech SA

twitter    linkedin

This website uses cookies to track its audience and improve its content.

By continuing to browse this website, you agree to the use of such cookies.